header background

Mnemosyne Pharmaceuticals

Mnemosyne Pharmaceuticals is focused on the discovery and development of small molecule drugs to treat neuropsychiatric disorders. Mnemosyne is currently developing a new class of drugs, the Subunit-selective NMDA Receptor Modulators (SNRMs), as a potential candidate for treatment for schizophrenia, Alzheimer’s disease, recovery from stroke and traumatic brain injury, and attention deficit/hyperactivity disorder (ADHD). Strong evidence indicates that a principal underlying cause of schizophrenia is defective NMDA receptor function, and Mnemosyne’s R&D aims to potentiate a specific NMDA subunit with its SNRM product candidates to provide therapeutic benefit for cognition, and also impact the positive and negative symptoms of schizophrenia.

 


NVCA